Xinyi Bao

Xinyi Bao


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
LZLifang Zhang
Lifang Zhang
YDYili Ding
Yili Ding
XBXinyi Bao
Xinyi Bao
Vishwa DeepakVishwa Deepak
Vishwa Deepak
Theasaponin E2 (TE2) is a triterpenoid saponin isolated from Camellia sinensis seeds with reported anti-inflammatory, antibacterial, and antitumor activities; however, its effects on osteoclasts remain unclear. In this study, TE2 markedly inhibited RANKL-induced osteoclast differentiation in RAW264.7 cells without affecting precursor-cell viability. TE2 also significantly reduced the number and viability of mature, differentiated osteoclasts. Mechanistically, TE2 suppressed RANKL-induced phosphorylation of AKT at Ser473 and GSK-3β at Ser9, as determined by ELISA. Molecular docking predicted that TE2 could interact with the interdomain allosteric pocket of AKT1 at the pleckstrin homology–kinase domain interface (PDB ID: 7NH5; docking score, −9.8 kcal/mol) and the ATP-binding pocket of GSK-3β (PDB ID: 5K5N; docking score, −7.7 kcal/mol). The selected docking poses contained multiple hydrogen-bonding interactions with donor–acceptor distances of 2.79–3.19 Å. Collectively, these findings indicate that TE2 suppresses osteoclast differentiation and reduces mature osteoclast viability, potentially through modulation of the AKT/GSK-3β signaling axis. TE2 may therefore represent a promising natural-product candidate for further investigation in conditions characterized by excessive osteoclast-mediated bone resorption.

Verified
Journal Article
Open access
PDF file
LZLifang Zhang
Lifang Zhang
YDYili Ding
Yili Ding
XBXinyi Bao
Xinyi Bao
Vishwa DeepakVishwa Deepak
Vishwa Deepak
Theasaponin E2 (TE2) is a triterpenoid saponin isolated from Camellia sinensis seeds with reported anti-inflammatory, antibacterial, and antitumor activities; however, its effects on osteoclasts remain unclear. In this study, TE2 markedly inhibited RANKL-induced osteoclast differentiation in RAW264.7 cells without affecting precursor-cell viability. TE2 also significantly reduced the number and viability of mature, differentiated osteoclasts. Mechanistically, TE2 suppressed RANKL-induced phosphorylation of AKT at Ser473 and GSK-3β at Ser9, as determined by ELISA. Molecular docking predicted that TE2 could interact with the interdomain allosteric pocket of AKT1 at the pleckstrin homology–kinase domain interface (PDB ID: 7NH5; docking score, −9.8 kcal/mol) and the ATP-binding pocket of GSK-3β (PDB ID: 5K5N; docking score, −7.7 kcal/mol). The selected docking poses contained multiple hydrogen-bonding interactions with donor–acceptor distances of 2.79–3.19 Å. Collectively, these findings indicate that TE2 suppresses osteoclast differentiation and reduces mature osteoclast viability, potentially through modulation of the AKT/GSK-3β signaling axis. TE2 may therefore represent a promising natural-product candidate for further investigation in conditions characterized by excessive osteoclast-mediated bone resorption.

Verified
Journal Article
Open access
PDF file
LZLifang Zhang
Lifang Zhang
CXChengxu Xie
Chengxu Xie
XBXinyi Bao
Xinyi Bao
XLXiaohan Li
Xiaohan Li
HVHeriberto Velez
Heriberto Velez
Vishwa DeepakVishwa Deepak
Vishwa Deepak
Excessive osteoclast formation is a key contributor to pathological bone loss in disorders such as osteoporosis and rheumatoid arthritis. Asarinin, a natural lignan, has not previously been examined in the context of osteoclast differentiation. Here, we investigated the anti-osteoclastogenic effects of asarinin using RANKL-stimulated RAW264.7 cells. Asarinin significantly suppressed TRAP-positive multinucleated osteoclast formation. Mechanistically, asarinin selectively inhibited RANKL-induced phosphorylation of p38 and ERK MAPKs, leading to reduced c-Fos expression and inhibition of NFATc1 activation. In addition, asarinin disrupted actin ring formation in mature osteoclasts. Collectively, these findings identify asarinin as a pathway-selective inhibitor of osteoclast differentiation, acting through a mechanism consistent with modulation of the p38/ERK–c-Fos–NFATc1 signaling cascade while sparing parallel signaling pathways.